Mahoney Stephen F.
- SEC CIK
- 0001741389
No open-market purchases or sales filed in the past year.
Current role at each company
- VRDN Viridian Therapeutics, Inc.President and CEOas of Mar 9, 2026
- DNTH Dianthus Therapeutics, Inc.See Remarksas of Dec 2, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Mahoney Stephen F. as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
VRDN Viridian Therapeutics, Inc.
President and CEO1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Mahoney Stephen F.President and CEO | PPurchase | +21.4K | $23.33 | +$499.3K | New position21.4K after |
DNTH Dianthus Therapeutics, Inc.
See Remarks1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 20, 2021 (view filing) | Sep 16 | 4 days | Mahoney Stephen F.See Remarks | SSale | −5.74K | $6.73 | −$38.6K | −28.7%14.3K after |